Back to Search
Start Over
BioXcel Therapeutics Announces FDA Acceptance for Filing of NDA for BXCL501 for the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders I and II
- Source :
- GlobeNewswire. May 19, 2021
- Publication Year :
- 2021
-
Abstract
- NEW HAVEN, May 19, 2021 (GLOBE NEWSWIRE via COMTEX) -- FDA sets PDUFA action date for January 5, 2022 If approved, BXCL501 would represent the first major advancement in the [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- GlobeNewswire
- Publication Type :
- News
- Accession number :
- edsgcl.662279167